JND3229

SKU: orb1707161

Description

JND3229 is a reversible inhibitor targeting the EGFR C797S mutation, demonstrating potent activity against resistant NSCLC cell lines (IC50 5.8 nM for L858R/T790M/C797S). It shows robust anti-proliferative effects in vitro and effectively inhibits tumor growth in vivo, making it a valuable tool for oncology research, particularly in non-small cell lung cancer.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 2260886-64-2
• MW: 617.18
• Purity: 98.75% (May vary between batches)
• Formula: C₃₃H₄₁ClN₈O₂
• SMILES: CCC(=O)N[C@H]1CC[C@@H](CC1)N1C(=O)N(Cc2cnc(Nc3ccc(N4CCN(C)CC4)c(C)c3)nc12)c1ccccc1Cl
• Target: EGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.62 mM);DMSO:11.7 mg/mL (18.96 mM)

Bioactivity

• In Vivo:
  JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo.
• In Vitro:
  JND3229 potently inhibits the proliferation of BaF3 cells (harboring the EGFRL858R/T790M/C797S and EGFR19D/T790M/C797Smutations), NCI-H1975 NSCLC cells (with EGFRT790M mutation) and A431 cancer cells (overexpressing EGFRWT) with IC50 values of 0.51, 0.32, 0.31 and 0.27 µM, respectively. JND3229 (0.1, 0.3, 1, 3, 10 µM; 2 h) potently inhibits the phosphorylation of EGFRL858R/T790M/C797S and EGFR19D/T790M/C797S in engineering BaF3 cells.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

JND 3229, JND3229, JND-3229, EGFR

Compound Identifiers

PubChem CID

137628688